CYANOCOBALAMIN INJECTION, USP

Manufacturer
American Regent, Inc.
Effective date
2023-10-31
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
12
Source
full-release
Hydrated at
2026-05-31 20:54:27

Label at a glance#

ProductCyanocobalamin
Active ingredientCYANOCOBALAMIN
Label structure17 sections

Indications and uses

Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions:  Addisonian (pernicious) anemia  Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy  Fish tapeworm infestation  Malignancy of pancreas or bowel  Folic acid deficiency It may be pos...

Dosage and administration

Avoid using the intravenous route. Use of this product intravenously will result in almost all of the vitamin being lost in the urine. Pernicious Anemia: Parenteral vitamin B 12 is the recommended treatment and will be required for the remainder of the patient's life. The oral form is not dependable. A dose of 100 mcg daily for 6 or 7 days should be administered by intramuscular or deep subcutaneous injection. If ...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION:

DESCRIPTION SECTION

Cyanocobalamin Injection, USP is a sterile solution of cyanocobalamin for intramuscular or subcutaneous injection. Each mL contains 1,000 mcg cyanocobalamin.

Each vial also contains Sodium Chloride, 0.9%. Benzyl Alcohol, 1.5%, is present as a preservative. Hydrochloric acid and/or sodium hydroxide may have been added during manufacture to adjust the pH (range 4.5-7.0).

Cyanocobalamin appears as dark red crystals or as an amorphous or crystalline red powder. It is very hygroscopic in the anhydrous form, and sparingly soluble in water (1:80). It is stable to autoclaving for short periods at 121°C. The vitamin B12 coenzymes are very unstable in light.

The chemical name is 5,6-dimethyl-benzimidazolyl cyanocobamide; the molecular formula is C63H88CoN14O14P. The cobalt content is 4.34%. The molecular weight is 1355.39.

The structural formula is represented below.

Structural Formula
Structural Formula

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

Vitamin B12 is essential to growth, cell reproduction, hematopoiesis, and nucleoprotein and myelin synthesis.

Cyanocobalamin is quantitatively and rapidly absorbed from intramuscular and subcutaneous sites of injection; the plasma level of the compound reaches its peak within 1 hour after intramuscular injection. Absorbed vitamin B12 is transported via specific B12 binding proteins, transcobalamin I and II to the various tissues. The liver is the main organ for vitamin B12 storage.

Within 48 hours after injection of 100 or 1,000 mcg of vitamin B12, 50 to 98% of the injected dose may appear in the urine. The major portion is excreted within the first eight hours. Intravenous administration results in even more rapid excretion with little opportunity for liver storage.

Gastrointestinal absorption of vitamin B12 depends on the presence of sufficient intrinsic factor and calcium ions. Intrinsic factor deficiency causes pernicious anemia, which may be associated with subacute combined degeneration of the spinal cord. Prompt parenteral administration of vitamin B12 prevents progression of neurologic damage.

The average diet supplies about 5 to 15 mcg/day of vitamin B12 in a protein-bound form that is available for absorption after normal digestion. Vitamin B12 is not present in foods of plant origin, but is abundant in foods of animal origin. In people with normal absorption, deficiencies have been reported only in strict vegetarians who consume no products of animal origin (including no milk products or eggs).

Vitamin B12 is bound to intrinsic factor during transit through the stomach; separation occurs in the terminal ileum in the presence of calcium, and vitamin B12 enters the mucosal cell for absorption. It is then transported by the transcobalamin binding proteins. A small amount (approximately 1% of the total amount ingested) is absorbed by simple diffusion, but this mechanism is adequate only with very large doses. Oral absorption is considered too undependable to rely on in patients with pernicious anemia or other conditions resulting in malabsorption of vitamin B12.

Cyanocobalamin is the most widely used form of vitamin B12, and has hematopoietic activity apparently identical to that of the antianemia factor in purified liver extract. Hydroxycobalamin is equally as effective as cyanocobalamin, and they share the cobalamin molecular structure.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

Cyanocobalamin is indicated for vitamin B12 deficiencies due to malabsorption which may be associated with the following conditions:

  •  Addisonian (pernicious) anemia
  •  Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy
  •  Fish tapeworm infestation
  •  Malignancy of pancreas or bowel
  •  Folic acid deficiency

It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin.

Requirements of vitamin B12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation.

Cyanocobalamin Injection, USP is also suitable for the vitamin B12 absorption test (Schilling test).

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Sensitivity to cobalt and/or vitamin B12 is a contraindication.

WARNINGS:

WARNINGS SECTION

Patients with early Leber's disease (hereditary optic nerve atrophy) who were treated with cyanocobalamin suffered severe and swift optic atrophy.

Hypokalemia and sudden death may occur in severe megaloblastic anemia which is treated intensely.

Anaphylactic shock and death have been reported after parenteral vitamin B12 administration. An intradermal test dose is recommended before Cyanocobalamin Injection, USP is administered to patients suspected of being sensitive to this drug.

This product contains Benzyl Alcohol. Benzyl Alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired.

Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

PRECAUTIONS:

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General Precautions: Vitamin B12 deficiency that is allowed to progress for longer than 3 months may produce permanent degenerative lesions of the spinal cord. Doses of folic acid greater than 0.1 mg per day may result in hematologic remission in patients with vitamin B12 deficiency. Neurologic manifestations will not be prevented with folic acid, and if not treated with vitamin B12, irreversible damage will result.

Doses of cyanocobalamin exceeding 10 mcg daily may produce hematologic response in patients with folate deficiency. Indiscriminate administration may mask the true diagnosis.

INFORMATION FOR PATIENTS SECTION

Information for Patients: Patients with pernicious anemia should be informed that they will require monthly injections of vitamin B12 for the remainder of their lives. Failure to do so will result in return of the anemia and in development of incapacitating and irreversible damage to the nerves of the spinal cord. Also, patients should be warned about the danger of taking folic acid in place of vitamin B12, because the former may prevent anemia but allow progression of subacute combined degeneration.

A vegetarian diet which contains no animal products (including milk products or eggs) does not supply any vitamin B12. Patients following such a diet, should be advised to take oral vitamin B12 regularly. The need for vitamin B12 is increased by pregnancy and lactation. Deficiency has been recognized in infants of vegetarian mothers who were breast fed, even though the mothers had no symptoms of deficiency at the time.

LABORATORY TESTS SECTION

Laboratory Tests: During the initial treatment of patients with pernicious anemia, serum potassium must be observed closely the first 48 hours and potassium replaced if necessary.

Hematocrit, reticulocyte count, vitamin B12, folate and iron levels should be obtained prior to treatment. Hematocrit and reticulocyte counts should be repeated daily from the fifth to seventh days of therapy and then frequently until the hematocrit is normal. If folate levels are low, folic acid should also be administered. If reticulocytes have not increased after treatment or if reticulocyte counts do not continue at least twice normal as long as the hematocrit is less than 35%, diagnosis or treatment should be reevaluated. Repeat determinations of iron and folic acid may reveal a complicating illness that might inhibit the response of the marrow.

Patients with pernicious anemia have about 3 times the incidence of carcinoma of the stomach as the general population, so appropriate tests for this condition should be carried out when indicated.

DRUG & OR LABORATORY TEST INTERACTIONS SECTION

Drug/Laboratory Test Interactions: Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.

Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long term studies in animals to evaluate carcinogenic potential have not been done. There is no evidence from long-term use in patients with pernicious anemia that cyanocobalamin is carcinogenic. Pernicious anemia is associated with an increased incidence of carcinoma of the stomach, but this is believed to be related to the underlying pathology and not to treatment with cyanocobalamin.

PREGNANCY SECTION

Pregnancy: Teratogenic Effects. Pregnancy Category C: Adequate and well-controlled studies have not been done in pregnant women. However, vitamin B12 is an essential vitamin and requirements are increased during pregnancy. Amounts of vitamin B12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for pregnant women (4 mcg daily) should be consumed during pregnancy.

NURSING MOTHERS SECTION

Nursing Mothers: Vitamin B12 is known to be excreted in human milk. Amounts of vitamin B12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for lactating women (4 mcg daily) should be consumed during lactation.

PEDIATRIC USE SECTION

Pediatric Use: Intake in children should be in the amount (0.5 to 3 mcg daily) recommended by the Food and Nutrition Board, National Academy of Science-National Research Council.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

Generalized: Anaphylactic shock and death have been reported with administration of parenteral vitamin B12 (see WARNINGS).

Cardiovascular: Pulmonary edema and congestive heart failure early in treatment; peripheral vascular thrombosis.

Hematological: Polycythemia vera

Gastrointestinal: Mild transient diarrhea

Dermatological: Itching; transitory exanthema

Miscellaneous: Feeling of swelling of entire body

OVERDOSAGE:

OVERDOSAGE SECTION

No overdosage has been reported with this drug.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

Avoid using the intravenous route. Use of this product intravenously will result in almost all of the vitamin being lost in the urine.

SPL UNCLASSIFIED SECTION

Pernicious Anemia: Parenteral vitamin B12 is the recommended treatment and will be required for the remainder of the patient's life. The oral form is not dependable. A dose of 100 mcg daily for 6 or 7 days should be administered by intramuscular or deep subcutaneous injection. If there is clinical improvement and if a reticulocyte response is observed, the same amount may be given on alternate days for seven doses, then every 3 to 4 days for another 2 to 3 weeks. By this time hematologic values should have become normal. This regimen should be followed by 100 mcg monthly for life. Folic acid should be administered concomitantly if needed.

SPL UNCLASSIFIED SECTION

Patients with Normal Intestinal Absorption: Where the oral route is not deemed adequate, initial treatment similar to that for patients with pernicious anemia may be indicated depending on the severity of the deficiency. Chronic treatment should be with an oral B12 preparation. If other vitamin deficiencies are present, they should be treated.

SPL UNCLASSIFIED SECTION

Schilling Test: The flushing dose is 1,000 mcg.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Cyanocobalamin Injection, USP 1,000 mcg/mL

NDC 0517-0031-25           1 mL Multiple-Dose Vial             Boxes of 25

NDC 0517-0032-25           10 mL Multiple-Dose Vial           Boxes of 25

NDC 0517-0130-01           30 mL Multiple-Dose Vial           Boxes of 1

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).

PROTECT THE PRODUCT FROM LIGHT.

IN0031
Rev. 01/2021
MG #10565

ARL LogoARL Logo

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 1 mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container

NDC 0517-0031-01

Rx Only

Cyanocobalamin Injection, USP

1,000 mcg/mL

For IM or SC Use Only

1 mL Multiple-Dose Vial

AMERICAN REGENT, INC.
SHIRLEY, NY 11967

1 mL Container Label1 mL Container Label

Carton

NDC 0517-0031-25

Rx Only

Cyanocobalamin Injection, USP

1,000 mcg/mL

For Intramuscular or Subcutaneous Use Only

25 x 1 mL Multiple-Dose Vials

AMERICAN REGENT, INC.
SHIRLEY, NY 11967

Carton Labeling (1 mL)Carton Labeling (1 mL)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 10 mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container

NDC 0517-0032-01

CYANOCOBALAMIN INJECTION, USP

10,000 mcg/10 mL

(1,000 mcg/mL)

10 mL MULTIPLE DOSE VIAL

FOR IM OR SC USE ONLY

Rx Only

AMERICAN REGENT, INC.
SHIRLEY, NY 11967

10 mL Container Label10 mL Container Label

Carton

CYANOCOBALAMIN INJECTION, USP

10,000 mcg/10 mL (1,000 mcg/mL)

NDC 0517-0032-25

25 x 10 mL MULTIPLE DOSE VIALS

FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY

Rx Only

Each mL contains: Cyanocobalamin 1000 mcg, Benzyl Alcohol 1.5%, Sodium Chloride 0.9%, Water for Injection q.s. pH (range 4.5 – 7.0) adjusted with Hydrochloric Acid and/or Sodium Hydroxide. WARNING: PROTECT FROM LIGHT. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature). Directions for Use: See Package Insert.

AMERICAN REGENT, INC.
SHIRLEY, NY 11967

Rev. 5/14

Carton
Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 30 mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container

NDC 0517-0130-01

Rx Only

CYANOCOBALAMIN INJECTION, USP

30,000 mcg/30 mL
(1,000 mcg/mL)

30 mL Multiple-Dose Vial

For IM or SC Use Only

AMERICAN REGENT, INC.
SHIRLEY, NY 11967

30 mL Vial Label30 mL Vial Label

Carton

NDC 0517-0130-01

30 mL MULTIPLE DOSE VIAL

CYANOCOBALAMIN INJECTION, USP

30,000 mcg/30 mL (1,000 mcg/mL)

FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY

Rx Only

AMERICAN REGENT, INC.|
SHIRLEY, NY 11967

Carton Labeling (30 mL)Carton Labeling (30 mL)

Serialization Label - 2 mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Serialization Label - 2 mL
Serialization Label - 2 mL

Serialization Label - 10 mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Serialization Label - 10 mL
Serialization Label - 10 mL

Serialization Label - 30 mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Serialization Label - 30 mL
Serialization Label - 30 mL

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309594cyanocobalamin 1000 MCG/ML Injectable SolutionPSN12
309594vitamin B12 1 MG/ML Injectable SolutionSCD12
309594cyanocobalamin 1 MG/ML Injectable SolutionSY12
309594cyanocobalamin 1000 MCG/ML Injectable SolutionSY12

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CYANOCOBALAMIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b82b4008-22fd-05f5-6cc6-c0a6e81c65b8Product name220240805
d206bb34-ea65-399d-70d9-834f22dc2c18Product name320170724
9869efd7-d6dd-0665-5b67-53adbe6ef15eProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0517-0031-01Cyanocobalamin1 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION112
0517-0031-25Cyanocobalamin25 in 1 TRAYINJECTION, SOLUTION2512
0517-0032-01Cyanocobalamin10 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION1012
0517-0032-25Cyanocobalamin25 in 1 TRAYINJECTION, SOLUTION2512
0517-0130-01Cyanocobalamin1 in 1 BOXINJECTION, SOLUTION112
0517-0130-01Cyanocobalamin30 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION3012

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0517-0031CYANOCOBALAMIN INJECTION, SOLUTION [AMERICAN REGENT, INC.]12Current NDC, Legacy NDC, 2 package rows20231101_2fb653d6-e2b2-4969-831b-c0dc37b9c0cc.zip
0517-0032CYANOCOBALAMIN INJECTION, SOLUTION [AMERICAN REGENT, INC.]12Current NDC, Legacy NDC, 2 package rows20231101_2fb653d6-e2b2-4969-831b-c0dc37b9c0cc.zip
0517-0130CYANOCOBALAMIN INJECTION, SOLUTION [AMERICAN REGENT, INC.]12Current NDC, Legacy NDC, 2 package rows20231101_2fb653d6-e2b2-4969-831b-c0dc37b9c0cc.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0517-0031-01ML - Milliliter0517-003163a936e0-d7e0-4346-b5c7-50ddd17e550812019-04-11
0517-0031-25ML - Milliliter0517-0031e8df80b8-81e5-4fc5-8235-ff942480e1a612012-07-24
0517-0032-01ML - Milliliter0517-0032c1c65471-d8c4-43b0-833d-176d37da951412019-10-07
0517-0032-25ML - Milliliter0517-00328f4147eb-e2b1-4edd-a70d-63bf6863a93412012-07-24
0517-0130-01ML - Milliliter0517-013086eb5f38-6f72-489e-94ed-58fdb6bc85b612019-08-06
0517-0130-05ML - Milliliter0517-0130a0336369-2b53-46f6-a047-3d2860111f8712012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CYANOCOBALAMINACTIVE INGREDIENTP6YC3EG2045
CYANOCOBALAMINACTIVE MOIETYP6YC3EG2045
BENZYL ALCOHOLINACTIVE INGREDIENTLKG8494WBH5
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8X5
WATERINACTIVE INGREDIENT059QF0KO0R5

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 32 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / INTRAMUSCULAR500 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / SUBCUTANEOUS0.95 %w/vExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / SUBCUTANEOUS0.95 %w/vExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / SUBCUTANEOUS0.95 %w/vExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / SUBCUTANEOUS0.95 %w/vExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / SUBCUTANEOUS0.95 %w/vExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / INTRAMUSCULAR500 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / INTRAMUSCULAR500 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / SUBCUTANEOUS0.95 %w/vExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / INTRAMUSCULAR500 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / INTRAMUSCULAR500 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / SUBCUTANEOUS0.95 %w/vExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / SUBCUTANEOUS0.95 %w/vExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / INTRAMUSCULAR500 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / INTRAMUSCULAR500 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHINJECTION, SOLUTION / INTRAMUSCULAR500 mgExact identifier — unii+route+dosage form
16 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A080737-001CYANOCOBALAMINCYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A080737-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19823bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19823a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A080737-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A080737-001AP184e616aacf4f…
2026-08-18 06:07:402026-07A080737-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A080737-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A080737-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08A080737-001AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A080737-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A080737-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A080737-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A080737-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A080737-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A080737-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A080737-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A080737-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A080737-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A080737-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A080737-001AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A080737-001AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A080737-001AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A080737-001AP14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A080737-001AP174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A080737-001AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A080737-001AP1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A080737-001AP187673890dc5c…
2021-03-12 10:30 UTC2021-03A080737-001AP15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A080737-001AP18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A080737-001AP1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A080737-001AP13f01610625f2…
2019-09-15 20:21 UTC2019-09A080737-001AP1b00525d2431f…
2019-07-19 19:46 UTC2019-07A080737-001AP1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A080737-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A080737-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A080737-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A080737-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A080737-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A080737-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A080737-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05A080737-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01A080737-001AP13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A080737-001AP13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A080737-001AP1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CyanocobalaminCYANOCOBALAMINAmerican Regent, Inc.2fb653d6-e2b2-4969-831b-c0dc37b9c0cc2023-10-31Warnings, Adverse reactionsExact identifier
ndc (package): 0517-0031-01
ndc (package): 0517-0031-25
ndc (package): 0517-0032-25
ndc (package): 0517-0130-01
ndc (package): 0517-0032-01
ndc (product): 0517-0032
ndc (product): 0517-0130
ndc (product): 0517-0031
ndc11 (package): 00517003225
ndc11 (package): 00517003201
ndc11 (package): 00517013001
ndc11 (package): 00517003125
ndc11 (package): 00517003101
spl id: 28421ba1-7e37-429c-9c66-62cc36f5847c
spl set id: 2fb653d6-e2b2-4969-831b-c0dc37b9c0cc

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.